Bioventus Inc.
BVS
$8.61
$0.101.12%
NASDAQ
| 03/28/2026 | 12/31/2025 | 09/27/2025 | 06/28/2025 | 03/29/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.52% | -0.91% | 1.58% | 5.08% | 8.60% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.52% | -0.91% | 1.58% | 5.08% | 8.60% |
| Cost of Revenue | -2.36% | -2.77% | -0.76% | 1.71% | 2.61% |
| Gross Profit | 3.39% | -0.02% | 2.73% | 6.77% | 11.75% |
| SG&A Expenses | -2.17% | -5.19% | -1.46% | 3.11% | 7.98% |
| Depreciation & Amortization | -30.03% | -25.16% | -22.39% | -16.67% | -11.55% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -3.09% | -4.85% | -1.79% | 2.26% | 5.94% |
| Operating Income | 71.14% | 58.89% | 67.00% | 63.53% | 75.27% |
| Income Before Tax | 166.90% | 149.12% | 118.97% | 102.49% | -90.32% |
| Income Tax Expenses | 85.72% | 70.43% | 132.76% | 131.68% | -653.16% |
| Earnings from Continuing Operations | 178.52% | 157.97% | 117.29% | 99.12% | -59.62% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -159.89% | -141.58% | -114.38% | -101.76% | 81.03% |
| Net Income | 184.09% | 162.93% | 118.14% | 98.34% | -54.17% |
| EBIT | 71.14% | 58.89% | 67.00% | 63.53% | 75.27% |
| EBITDA | 29.81% | 25.31% | 20.37% | 16.06% | 15.25% |
| EPS Basic | 180.98% | 160.31% | 117.36% | 98.16% | -50.75% |
| Normalized Basic EPS | 57.85% | 28.68% | 51.38% | 42.15% | 227.51% |
| EPS Diluted | 177.13% | 157.85% | 116.98% | 97.70% | -51.03% |
| Normalized Diluted EPS | 52.72% | 24.25% | 47.31% | 37.63% | 227.51% |
| Average Basic Shares Outstanding | 2.67% | 3.22% | 3.55% | 3.89% | 3.54% |
| Average Diluted Shares Outstanding | 6.09% | 5.62% | 5.10% | 4.69% | 3.54% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |